Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PCV24 in Adults
NCT07025876Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Sinovac PCV24 in pneumococcal disease (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Incidence of adverse reactions after vaccination. Started Nov 2023; status: completed.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07025876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025876.